These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
13. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M; Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106 [TBL] [Abstract][Full Text] [Related]
14. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia. Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219 [TBL] [Abstract][Full Text] [Related]
15. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561 [TBL] [Abstract][Full Text] [Related]
16. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792 [TBL] [Abstract][Full Text] [Related]
18. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165 [TBL] [Abstract][Full Text] [Related]
19. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180 [TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers ME; Maris MB; Laport GG; Chauncey TR; Lange T; Langston AA; Storer B; Georges GE Haematologica; 2011 Aug; 96(8):1113-20. PubMed ID: 21508120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]